{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advate&page=8",
    "query": {
      "intervention": "Advate",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 180,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advate&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advate&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T08:08:11.155Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03199794",
      "title": "Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acquired Hemophilia A"
      ],
      "interventions": [
        {
          "name": "OBIZUR",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2016-12-14",
      "completion_date": "2021-07-30",
      "has_results": false,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 6,
      "location_summary": "Gainesville, Florida • Detroit, Michigan • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199794"
    },
    {
      "nct_id": "NCT01181128",
      "title": "Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Factor VIII (rFVIIIFc)",
          "type": "DRUG"
        },
        {
          "name": "Advate®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 165,
      "start_date": "2010-11",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 21,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01181128"
    },
    {
      "nct_id": "NCT03417245",
      "title": "A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "fitusiran",
          "type": "DRUG"
        },
        {
          "name": "factor concentrates",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2018-03-01",
      "completion_date": "2021-07-14",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417245"
    },
    {
      "nct_id": "NCT00214734",
      "title": "ADVATE Post Authorization Safety Surveillance",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rAHF-PFM",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 108,
      "start_date": "2004-10-14",
      "completion_date": "2007-03-02",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00214734"
    },
    {
      "nct_id": "NCT00357656",
      "title": "Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant Protein-Free Factor VIII (rAHF-PFM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 85,
      "start_date": "2006-05-29",
      "completion_date": "2015-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357656"
    },
    {
      "nct_id": "NCT03876301",
      "title": "Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood Coagulation Disorder",
        "Blood Coagulation Disorders, Inherited",
        "Coagulation Protein Disorders",
        "Hemophilia A",
        "Genetic Diseases, Inborn",
        "Genetic Diseases, X-Linked",
        "Hematologic Diseases",
        "Hemorrhagic Disorders",
        "Factor VIII Deficiency"
      ],
      "interventions": [
        {
          "name": "Standard of Care FVIII Replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2019-01-21",
      "completion_date": "2023-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03876301"
    },
    {
      "nct_id": "NCT03754790",
      "title": "Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Fitusiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 281,
      "start_date": "2019-01-09",
      "completion_date": "2026-09-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03754790"
    },
    {
      "nct_id": "NCT02093897",
      "title": "Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rVIII-SingleChain",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "Up to 11 Years · Male only"
      },
      "enrollment_count": 84,
      "start_date": "2014-03",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-27",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Chicago, Illinois",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02093897"
    },
    {
      "nct_id": "NCT03204539",
      "title": "INdividualized ITI Based on Fviii(ATE) Protection by VWF",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor",
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Wilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 1,
      "start_date": "2017-06-01",
      "completion_date": "2019-07-19",
      "has_results": true,
      "last_update_posted_date": "2020-05-29",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • San Diego, California • New Orleans, Louisiana",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03204539"
    },
    {
      "nct_id": "NCT01138501",
      "title": "Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A"
      ],
      "interventions": [
        {
          "name": "turoctocog alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "Up to 11 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2010-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-10-22T08:08:11.155Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Orange, California • Torrance, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01138501"
    }
  ]
}